- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Balancing Clinical and Economic Considerations in Treatment Adoption
Panelists discuss how integrating clinical efficacy with cost-effectiveness ensures sustainable adoption of MASH therapies.
EP: 1.Understanding the Metabolic–Hepatic Connection in MASH
EP: 2.Enhancing Early Detection and Diagnosis in MASH
EP: 3.Recognizing Risk and the Broader Health Impact in MASH
EP: 4.Evidence for GLP-1 Therapy in MASH
EP: 5.Expanding the Therapeutic Horizon in MASH
EP: 6.Balancing Clinical and Economic Considerations in Treatment Adoption
Panelists discuss how to balance clinical effectiveness with economic realities when introducing costly new therapies. They examine practical factors in initiating GLP-1–based treatments for patients with multiple comorbidities, ensuring safety and optimization of outcomes.
They argue that investment in early intervention can yield long-term savings by preventing expensive complications like cirrhosis or hepatocellular carcinoma. Economic models and payer engagement are presented as critical tools for demonstrating real-world value.
Panelists close by emphasizing data-driven decision-making, encouraging health systems to track outcomes and costs to refine adoption strategies over time.
